RxDoctor Payments Data

Graham Abra, MD

Nephrology · Stanford, CANPI 1760644678

Payments from drug & device makers

$18,169in general payments, 2019–2025

Across 29 payments — averaging $626.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$6K
  • Fresenius USA Marketing, Inc.$5K
  • Baxter Healthcare$4K
  • Outset Medical Inc$2K
  • Nxstage Medical, Inc.$412
  • Otsuka America Pharmaceutical, Inc.$145
  • plus $41 from 3 others

What the payments were for

  • Consulting fees$13,03872%
  • Speaking & faculty fees$4502%
  • Travel & lodging$3,16817%
  • Food & beverage$1,4628%
  • Education$30%
  • Entertainment$490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,169 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$165,068
Medicare patients
308
Services billed
1,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol64$84,695
JardianceEmpagliflozin45$52,652
OzempicSemaglutide29$40,966
KerendiaFinerenone20$19,143
VeltassaPatiromer Calcium Sorbitex12$14,770
MounjaroTirzepatide12$11,717
RenvelaSevelamer Carbonate11$10,450
Sevelamer Carbonate22$6,426
ProcritEpoetin Alfa12$6,319
Calcium Acetate23$2,318
Eplerenone16$1,282
Atorvastatin Calcium63$596
Chlorthalidone41$576
Furosemide51$555
Torsemide17$553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$20$84,69564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.

Other nephrology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →